Stoke Therapeutics Presents Data From Multiple Studies of Ch

– Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modification –– Analysis of 72 patients treated in STK-001 clinical trials suggests that higher...

Related Keywords

United Kingdom , Massachusetts , United States , Orlando , Florida , Bedford , Cambridge , Cambridgeshire , American , Helen Cross , Joseph Sullivan , Archana Desurkar , Eric Rojas , Barry Ticho , Pediatric Epilepsy Center , Stoke Therapeutics Inc , Exchange Commission , University Of California San Francisco , International League Against Epilepsy , Company Annual Report On Form , Nasdaq , Augmentation Of Nuclear Gene Output , American Epilepsy Society , Stoke Therapeutics , Meeting December , Chief Medical Officer , California San Francisco , History Study , Dravet Syndrome Ages , Label Extension , Month Analysis , Observational Study , Investigate Cognition , Dravet Syndrome , California San , Kingdom Investigating Safety , Drug Exposure , Antisense Oligonucleotide , Childhood Epilepsy , Developmental Neuroscience Programme , Child Health , Honorary Consultant , Paediatric Neurology , International League Against , Open Label Extension , Previously Participated , Consultant Paediatric Neurologist , Sheffield Children , Hospital National Health Service Foundation , Dosing Regimens , Senior Vice President , Clinical Pharmacology , Targeted Augmentation , Nuclear Gene Output , Private Securities Litigation Reform Act , Annual Report , Investor Contacts , Investor Relations ,